Chipscreen's Treatment for Lymphoma Approved in China

Chipscreen Biosciences of Shenzhen received CFDA approval of Chidamide (Epidaza ® ), a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients. According to Chipscreen, Chidamide is world's first oral subtype-selective histone deacetylase (HDAC) inhibitor for PTCL to be granted approval. Chidamide, which was reviewed under a CFDA accelerated program, will be the first of Chipscreen's portfolio to be marketed. More details.... Share this with colleagues: // //